IBDEI0BD ; ; 17-FEB-2016
 ;;3.0;IB ENCOUNTER FORM IMP/EXP;;JUN 29, 2015
 Q:'DIFQR(358.3)  F I=1:2 S X=$T(Q+I) Q:X=""  S Y=$E($T(Q+I+1),4,999),X=$E(X,4,999) S:$A(Y)=126 I=I+1,Y=$E(Y,2,999)_$E($T(Q+I+1),5,99) S:$A(Y)=61 Y=$E(Y,2,999) X NO E  S @X=Y
Q Q
 ;;^UTILITY(U,$J,358.3,5133,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,5133,1,3,0)
 ;;=3^Amino-Acid Transport Disorders,Other
 ;;^UTILITY(U,$J,358.3,5133,1,4,0)
 ;;=4^E72.09
 ;;^UTILITY(U,$J,358.3,5133,2)
 ;;=^5002895
 ;;^UTILITY(U,$J,358.3,5134,0)
 ;;=N25.89^^27^330^23
 ;;^UTILITY(U,$J,358.3,5134,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,5134,1,3,0)
 ;;=3^Impaired Renal Tubular Function Disorders,Other
 ;;^UTILITY(U,$J,358.3,5134,1,4,0)
 ;;=4^N25.89
 ;;^UTILITY(U,$J,358.3,5134,2)
 ;;=^5015618
 ;;^UTILITY(U,$J,358.3,5135,0)
 ;;=E26.89^^27^330^12
 ;;^UTILITY(U,$J,358.3,5135,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,5135,1,3,0)
 ;;=3^Hyperaldosteronism,Other
 ;;^UTILITY(U,$J,358.3,5135,1,4,0)
 ;;=4^E26.89
 ;;^UTILITY(U,$J,358.3,5135,2)
 ;;=^5002737
 ;;^UTILITY(U,$J,358.3,5136,0)
 ;;=N25.81^^27^330^29
 ;;^UTILITY(U,$J,358.3,5136,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,5136,1,3,0)
 ;;=3^Secondary Hyperparathyroidism of Renal Origin
 ;;^UTILITY(U,$J,358.3,5136,1,4,0)
 ;;=4^N25.81
 ;;^UTILITY(U,$J,358.3,5136,2)
 ;;=^5015617
 ;;^UTILITY(U,$J,358.3,5137,0)
 ;;=E22.2^^27^330^28
 ;;^UTILITY(U,$J,358.3,5137,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,5137,1,3,0)
 ;;=3^SIADH
 ;;^UTILITY(U,$J,358.3,5137,1,4,0)
 ;;=4^E22.2
 ;;^UTILITY(U,$J,358.3,5137,2)
 ;;=^5002718
 ;;^UTILITY(U,$J,358.3,5138,0)
 ;;=E87.79^^27^330^10
 ;;^UTILITY(U,$J,358.3,5138,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,5138,1,3,0)
 ;;=3^Fluid Overload,Other
 ;;^UTILITY(U,$J,358.3,5138,1,4,0)
 ;;=4^E87.79
 ;;^UTILITY(U,$J,358.3,5138,2)
 ;;=^5003025
 ;;^UTILITY(U,$J,358.3,5139,0)
 ;;=E21.0^^27^330^27
 ;;^UTILITY(U,$J,358.3,5139,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,5139,1,3,0)
 ;;=3^Primary Hyperparathyroidism
 ;;^UTILITY(U,$J,358.3,5139,1,4,0)
 ;;=4^E21.0
 ;;^UTILITY(U,$J,358.3,5139,2)
 ;;=^331439
 ;;^UTILITY(U,$J,358.3,5140,0)
 ;;=E87.71^^27^330^30
 ;;^UTILITY(U,$J,358.3,5140,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,5140,1,3,0)
 ;;=3^Transfusion Associated Circulatory Overload
 ;;^UTILITY(U,$J,358.3,5140,1,4,0)
 ;;=4^E87.71
 ;;^UTILITY(U,$J,358.3,5140,2)
 ;;=^5003024
 ;;^UTILITY(U,$J,358.3,5141,0)
 ;;=D63.1^^27^331^1
 ;;^UTILITY(U,$J,358.3,5141,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,5141,1,3,0)
 ;;=3^Anemia in Chronic Kidney Disease
 ;;^UTILITY(U,$J,358.3,5141,1,4,0)
 ;;=4^D63.1
 ;;^UTILITY(U,$J,358.3,5141,2)
 ;;=^332908
 ;;^UTILITY(U,$J,358.3,5142,0)
 ;;=I12.0^^27^331^9
 ;;^UTILITY(U,$J,358.3,5142,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,5142,1,3,0)
 ;;=3^HTN w/ CKD w/ Stage 5 CKD/ESRD
 ;;^UTILITY(U,$J,358.3,5142,1,4,0)
 ;;=4^I12.0
 ;;^UTILITY(U,$J,358.3,5142,2)
 ;;=^5007065
 ;;^UTILITY(U,$J,358.3,5143,0)
 ;;=I95.1^^27^331^10
 ;;^UTILITY(U,$J,358.3,5143,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,5143,1,3,0)
 ;;=3^Hypotension,Orthostatic
 ;;^UTILITY(U,$J,358.3,5143,1,4,0)
 ;;=4^I95.1
 ;;^UTILITY(U,$J,358.3,5143,2)
 ;;=^60741
 ;;^UTILITY(U,$J,358.3,5144,0)
 ;;=I95.89^^27^331^11
 ;;^UTILITY(U,$J,358.3,5144,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,5144,1,3,0)
 ;;=3^Hypotension,Other
 ;;^UTILITY(U,$J,358.3,5144,1,4,0)
 ;;=4^I95.89
 ;;^UTILITY(U,$J,358.3,5144,2)
 ;;=^5008079
 ;;^UTILITY(U,$J,358.3,5145,0)
 ;;=N17.9^^27^331^12
 ;;^UTILITY(U,$J,358.3,5145,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,5145,1,3,0)
 ;;=3^Kidney Failure,Acute,Unspec
 ;;^UTILITY(U,$J,358.3,5145,1,4,0)
 ;;=4^N17.9
 ;;^UTILITY(U,$J,358.3,5145,2)
 ;;=^338532
 ;;^UTILITY(U,$J,358.3,5146,0)
 ;;=N18.5^^27^331^3
 ;;^UTILITY(U,$J,358.3,5146,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,5146,1,3,0)
 ;;=3^Chronic Kidney Disease,Stage 5
